A leader in Alzheimer’s disease research, TauRx’s mission is to discover, develop and commercialise innovative products for the diagnosis, treatment and cure of neurodegenerative diseases caused through protein aggregation.
From initial discovery through preclinical development to clinical trials, regulatory submission and product registration, we are working towards halting the progression of Alzheimer’s and other neurodegenerative diseases.
Using world-class proprietary drug discovery platforms, TauRx aims to halt the progression of Alzheimer’s, frontotemporal dementia and other neurodegenerative diseases with innovative treatments and diagnostics.
The company’s novel tau aggregation inhibitors (TAIs) target the formation (aggregation) of tau protein ‘tangles’ in the brain. The spread of tau tangles – the main driver in Alzheimer’s disease – is strongly correlated with dementia and they can develop in the brain up to 30 years before symptoms associated with dementia develop. TAIs work by dissolving existing tau tangles and preventing new tangles from forming.
Our lead compound, LMTX® – the first hopeful treatment for Alzheimer’s in more than a decade – inhibits aggregation of tau, synuclein, TPD-43 and huntingtin proteins. Patented as a novel chemical entity and chemically distinct from our initial rember® compound, LMTX® is currently in development for the treatment and prevention of Alzheimer’s disease and bvFTD.
The LMTX® Phase 3 clinical trial programme, conducted in over 20 countries and involving over 1,900 patients, has recently completed. Results are being reported during the second half of 2016.